Verrica Pharmaceuticals Inc. (VRCA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 22.44M USD | Liabilities, Current |
| Cash and equivalents | 11.20M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 10.94M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 2.71M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $22.44M | $11.20M | (m) | $10.94M | $2.71M | (m) |
| 2026-03-31 | (m) | $16.22M | $20.60M | (m) | $7.72M | $1.97M | (m) |
| 2025-12-31 | (m) | $16.44M | $30.15M | (m) | $5.26M | $2.24M | (m) |
| 2025-09-30 | (m) | $28.91M | $21.10M | (m) | $7.05M | $2.30M | (m) |
| 2025-06-30 | (m) | $29.22M | $15.40M | (m) | $9.19M | $2.52M | (m) |
| 2025-03-31 | (m) | $29.40M | $29.59M | (m) | $5.61M | $2.46M | (m) |
| 2024-12-31 | (m) | $29.01M | $46.33M | (m) | $48.00K | $2.46M | (m) |
| 2024-09-30 | (m) | $21.03M | $22.96M | (m) | $0.00 | $2.58M | (m) |
| 2024-06-30 | (m) | $20.05M | $31.93M | (m) | $10.03M | $2.70M | (m) |
| 2024-03-31 | (m) | $19.36M | $48.94M | (m) | $7.00M | $2.50M | (m) |
| 2023-12-31 | (m) | $17.02M | $69.55M | (m) | $4.25M | $1.02M | (m) |
| 2023-09-30 | (m) | $11.37M | $84.31M | (m) | $3.95M | $279.00K | (m) |
| 2023-06-30 | (m) | $5.73M | $55.14M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $2.64M | $59.95M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $3.46M | $34.27M | $0.00 | (m) | (m) | (m) |
| 2022-09-30 | (m) | $3.08M | $32.47M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $45.71M | $5.43M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $44.80M | $10.41M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $46.05M | $15.75M | $0.00 | (m) | (m) | (m) |
| 2021-09-30 | (m) | $46.37M | $20.44M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $45.28M | $24.71M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $44.66M | $44.10M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $39.48M | $10.69M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $39.00M | $17.20M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $38.70M | $48.93M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $3.30M | $54.49M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $3.35M | $9.24M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $4.33M | $10.60M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $4.28M | $19.85M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $3.06M | $24.43M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.48M | $10.27M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $2.45M | $38.31M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $3.13M | $103.15M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $27.48M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $616.00K | $8.66M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | $396.00K | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $506.00K | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $527.00K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |